ImmuneOncia Therapeutics Plunges More Than 10% in Aftermarket Trading
Predicted impact: Medium
Designation as unfaithful disclosure company was flagged earlier; the aftermarket drop is a market reaction, not new news.
ImmuneOncia Therapeutics이뮨온시아
424870 · KOSDAQ · ₩424870 · 이뮨온시아
₩2,515▼ ₩85 (3.27%)End-of-day · Oct 30, 2026 · End-of-day prices.
Price · 1Y −56.71%
- Market cap
- ₩230B
- Enterprise value
- ₩137B
- P/E
- —
- P/B
- 2.3×
- Dividend yield
- 0.0%
- ROE
- −28.1%
- Net margin
- —
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−84.4% from the high
₩2,300Today: ₩2,485 – ₩2,610₩16,110
Returns
- 1W−14.0%
- 1M−24.7%
- 3M−6.9%
- 6M−64.0%
- YTD−80.7%
- 1Y−56.7%
- Volume today
- 365,217
- 0.8× the 20-day average
- Traded today
- ₩925M
- Listed shares
- 91,402,269
- EPS (12 months)
- −₩308
- Earnings yield −12.3%
AI research · InitiationImmuneOncia Therapeutics: Pre-Revenue Biotech With Widening Losses and a Share Price Down 50.9% Over a YearThe data describes a pre-revenue biotech with sizeable losses, a low-debt balance sheet and a cash position funded by a recent capital raise.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 40 of 100 (50 is a normal day for this stock).
- SentimentNegativeNews: Shares fell sharply and a filing flags two disclosure lapses. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-25.4% over the last month; the price is below its 20-day average.
- News impactSome2 news items and filings in two weeks; 0 rated high impact, 2 medium.
Signals describe activity, not recommendations. Not financial advice.
ImmuneOncia Therapeutics stock overview
ImmuneOncia Therapeutics (이뮨온시아, KRX: 424870) is listed on KOSDAQ, in the Biotech & Pharma sector. ImmuneOncia develops antibody-based cancer immunotherapy drugs. Its shares closed at ₩2,515 on Oct 30, 2026, down 3.27% on the day, giving it a market value of ₩230B.
Key facts
- Market cap
- ₩230B
- Sector
- Biotech & Pharma
- Latest price change
- −3.27%
- As of
- Oct 30, 2026
- Main business
- ImmuneOncia develops antibody-based cancer immunotherapy drugs.
Quick answers about ImmuneOncia Therapeutics
- What does ImmuneOncia Therapeutics do?
- ImmuneOncia develops antibody-based cancer immunotherapy drugs. Its core assets are monoclonal antibodies targeting PD-L1 (IMC-001), CD47 (IMC-002), and a PD-L1 and CD47 bispecific antibody (IMC-201). Its business model is to develop drug candidates and license them to partners after early clinical stages, while also pursuing domestic commercialization of its Anti-PD-L1 antibody in South Korea.
- What is the market cap of ImmuneOncia Therapeutics?
- The market capitalisation of ImmuneOncia Therapeutics was ₩230B at the close on Oct 30, 2026.
- Who are the largest shareholders of ImmuneOncia Therapeutics?
- According to the latest official filings, the largest reported holders are Yuhan Corporation (57.23%, as of May 27, 2026); PAIK SOONMYUNG (0.12%, as of Jul 28, 2026).
- When is the next earnings report from ImmuneOncia Therapeutics?
- Korean companies rarely announce results dates in advance. Based on when ImmuneOncia Therapeutics filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
ImmuneOncia develops antibody-based cancer immunotherapy drugs. Its core assets are monoclonal antibodies targeting PD-L1 (IMC-001), CD47 (IMC-002), and a PD-L1 and CD47 bispecific antibody (IMC-201). Its business model is to develop drug candidates and license them to partners after early clinical stages, while also pursuing domestic commercialization of its Anti-PD-L1 antibody in South Korea. The company targets rare cancers such as NK/T-cell lymphoma and solid tumors, and plans partnering efforts mainly in China, East Asia, the United States and Europe.
Written by AI from the company's latest annual report.
- Korean name
- 이뮨온시아
- Sector
- Biotech & Pharma
- CEO
- 김흥태
- Founded
- Sep 2016
- Listed
- May 2025
- Listed shares
- 91,402,269
- Fiscal year ends
- Month 12
- Website
- www.immuneoncia.com/immun/
Similar companies
- Samsung Biologics207940 · ₩69T₩1,487,000+8.86%
- Celltrion068270 · ₩44T₩191,600+1.22%
- Alteogen196170 · ₩15T₩211,500−3.86%
- SK biopharmaceuticals326030 · ₩6.1T₩77,700−0.13%
- Yuhan000100 · ₩5.5T₩75,100+0.54%
- HLB028300 · ₩5.3T₩40,000+0.76%
- Hanmi Pharm128940 · ₩5.3T₩415,000+6.82%
- SAM Chun Dang Pharm000250 · ₩4.3T₩182,700−3.13%
Recent news
Recent filings
See all- Notice of Designation as Unfaithful Disclosure Entity (Two Cases of Non-Performance of Disclosure)Oct 28, 2026
- Investor relations (IR) eventOct 15, 2026
- Major management matter relevant to investorsSep 14, 2026
- Major management matter relevant to investorsSep 14, 2026
- Half-year report (Jun 2026)Aug 14, 2026
Titles in Korean until English translations are added.
Also known as: ImmuneOncia Therapeutics / 이뮨온시아 / 424870 / KRX:424870
Source: KRX statistical information